In Public Interest, India Caps Prices Of Several Top Selling MNC Brands
This article was originally published in PharmAsia News
Executive Summary
India’s drug pricing watchdog, the National Pharmaceutical Pricing Authority has brought under control 108 formulations of popular diabetes and cardiovascular drugs in a move that may leave a big hole in the sales and profits of several local and global companies.